CytoDyn Inc.

FOR THE LATEST DEVELOPING NEWS

Click Here

OHSU Leronlimab Study

Leronlimab on Spectrum News-LA West

Investment Community Conference Call on July 30

Proactive Investors interview on August 7

Special Meeting of Stockholders on July 22

We believe in the future of precision medicine

CytoDyn believes in the future of precision medicine... more specificity, less side effects. Our target, the CCR5 receptor, has been implicated in multiple disease processes from HIV, GVHD, NASH, stroke recovery, multiple sclerosis, Parkinson's disease, to metastatic cancer. Leronlimab, our CCR5 antagonist, is a once a week, subcutaneous injection. One molecule with multiple opportunities. With precision comes the opportunity for improved safety, convenience, and enhanced efficacy for the patient.

Welcome to the future of target specific, precision medicine. Welcome to CytoDyn.

We are a biotechnology company focused on developing innovative treatments for multiple therapeutic indications. Our lead candidate Leronlimab (PRO 140) belongs to a new class of therapeutics called viral-entry inhibitors and is one of the most advanced experimental monoclonal antibodies for HIV treatment.

Leronlimab’s Mechanism of Action for Immuno-oncology

About Our Company

Arrow Down

Leronlimab for HIV

A Fully Humanized Monoclonal Antibody

Leronlimab (PRO 140) is a fully humanized monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter T cells. Leronlimab (PRO 140) only blocks the precise site on CCR5 that HIV needs to enter the cell without interfering with the normal functions of CCR5.

Read More on Leronlimab

CCR5 for Cancer

Developing CCR5 Technology in Cancer Indications

Based on the work of of a leading oncologist and researcher who has played an instrumental role in identifying the role of CCR5 in cancer indications, we continue to develop CCR5 technology and have obtained promising results from various pre-clinical studies.

Read More on CCR5

The Science of Developing Monoclonal Antibodies

In the 1980s, a team of scientists developed a technique that fused a common type of tumor cell with a single mouse antibody-producing cell. The resulting hybrid cells all secreted the exact same antibody as the original mouse antibody-producing cell and thus came to be known as monoclonal antibodies. Since then, monoclonal antibodies have come to represent one of the fastest expanding opportunities in the biotechnology/pharma sector.

Learn About Our Science

Latest News

View all news

CytoDyn Announces Clinically Significant Top-line Results from its Phase 2 Trial in Mild-to-Moderate COVID-19 Patients

Read More

CytoDyn Seeks UK Approval of Leronlimab for HIV and COVID-19

Read More

CytoDyn Receives Positive DSMC Recommendation for Leronlimab Phase 3 COVID-19 Trial with No Safety Concerns

Read More